<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - CVTX</title>
<description>International Business News - CVTX</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>CV Therapeutics cuts loss on better Ranexa sales</title>
  <description>CV Therapeutics Inc. winnowed its loss by 26 percent in the third quarter, the biopharmaceutical company said Thursday, because of improved sales of its angina drug Ranexa and greater royalty and collaboration payments.</description>
    <link>http://www.ibtimes.com/articles/20081106/cv-therapeutics-cuts-loss-on-better-ranexa-sales.htm</link> 
  <pubDate>Thu, 06 Nov 2008 13:29:09 EST</pubDate>
  </item>


  <item>
  <title>CV says drug gets primary approval in angina</title>
  <description>The Food and Drug Administration approved Ranexa as a primary treatment for a kind of chest pain, maker CV Therapeutics Inc. said Thursday, adding to its earlier approval of the drug as a secondary treatment.</description>
    <link>http://www.ibtimes.com/articles/20081106/cv-says-drug-gets-primary-approval-in-angina.htm</link> 
  <pubDate>Thu, 06 Nov 2008 08:47:48 EST</pubDate>
  </item>


  <item>
  <title>CV Therapeutics gets longer angina drug review</title>
  <description>Biotechnology company CV Therapeutics Inc. said Monday the Food and Drug Administration will take longer than expected to review a request to approve its drug Ranexa as an initial treatment for angina.</description>
    <link>http://www.ibtimes.com/articles/20080728/cv-therapeutics-gets-longer-angina-drug-review.htm</link> 
  <pubDate>Mon, 28 Jul 2008 12:31:13 EDT</pubDate>
  </item>


  <item>
  <title>CV Therapeutics gets European OK for Ranexa</title>
  <description>Biotechnology company CV Therapeutics Inc. said Thursday European regulators approved its chronic angina drug Ranexa, which is called Ranolazine outside the U.S.</description>
    <link>http://www.ibtimes.com/articles/20080710/cv-therapeutics-gets-european-ok-for-ranexa.htm</link> 
  <pubDate>Thu, 10 Jul 2008 17:03:06 EDT</pubDate>
  </item>


  <item>
  <title>CV Therapeutics receives $10M milestone payment</title>
  <description>Biopharmaceutical company CV Therapeutics Inc. said Tuesday it has received a milestone payment of $10 million from TPG-Axon Capital related to the commercial launch of its stress agent Lexiscan.</description>
    <link>http://www.ibtimes.com/articles/20080624/cv-therapeutics-receives-10m-milestone-payment.htm</link> 
  <pubDate>Tue, 24 Jun 2008 09:47:46 EDT</pubDate>
  </item>


  <item>
  <title>Earnings roundup: Volvo, AMAG Pharmaceuticals</title>
  <description>Among the earnings stories for Friday, April 25, from AP Financial News: STOCKHOLM, Sweden (AP) _ Swedish truck maker Volvo AB said Friday that first-quarter profit rose 12 percent as higher sales in Europe and Asia more than offset weak demand in the United States.</description>
    <link>http://www.ibtimes.com/articles/20080425/earnings-roundup-volvo-amag-pharmaceuticals.htm</link> 
  <pubDate>Fri, 25 Apr 2008 10:41:55 EDT</pubDate>
  </item>


</channel>
</rss>